title: Aspirin resistance in systemic lupus erythematosus. A pilot study.
abstract: Systemic lupus erythematosus (SLE) patients are at increased risk of thrombosis and cardiovascular diseases. Aspirin is an effective treatment option for these patients. The aim of this study was to investigate the presence of aspirin resistance in SLE patients. We studied aspirin resistance in 33 SLE patients and nine healthy controls by using a Multiplate® impedance aggregometer (Dynabyte GmbH, Munich, Germany). Twenty-six SLE patients were on regular aspirin treatment. Aspirin resistance was found in five (19.2%) out of 26 patients who were on aspirin treatment. When the tests were repeated by adding acetylsalicylic acid in the medium, all of these patients became responsive to the aspirin. SLE disease activity, body mass index, smoking status, and the presence of anticardiolipin antibodies or positive lupus anticoagulant test results were no different in patients with or without aspirin resistance. (p>0.05 for all). Our results suggest that there may be a considerable number of SLE patients with aspirin resistance.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Hacettepe University Hospital, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Akdogan
authors.forename: L
authors.initials: L
authors.lastname: Kilic
authors.forename: U
authors.initials: U
authors.lastname: Akman
authors.forename: I
authors.initials: I
authors.lastname: Dogan
authors.forename: O
authors.initials: O
authors.lastname: Karadag
authors.forename: S A
authors.initials: SA
authors.lastname: Bilgen
authors.forename: Y
authors.initials: Y
authors.lastname: Buyukasik
authors.forename: S
authors.initials: S
authors.lastname: Kiraz
authors.forename: I
authors.initials: I
authors.lastname: Ertenli
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D004351:Drug Resistance; D017097:Electric Impedance; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010979:Platelet Function Tests; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D017153:Antibodies, Anticardiolipin; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: SLE; aspirin; aspirin resistance